Epidemiology and natural history of nonalcoholic fatty liver disease;Épidémiologie et histoire naturelle des hépatopathies stéatosiques «métaboliques»

Revue du Praticien

Volumn 62, Issue 10, 2012, Pages

  Pais, Raluca ^a   Ratziu, Vlad ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC LIVER DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; END STAGE LIVER DISEASE; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW; BIOLOGICAL MODEL; DISEASE COURSE; FATTY LIVER; LIVER; METABOLISM; PATHOLOGY; PREVALENCE; RISK FACTOR;

DISEASE PROGRESSION; FATTY LIVER; HUMANS; LIVER; MODELS, BIOLOGICAL; PREVALENCE; RISK FACTORS;

MLCS; MLOWN;

EID: 84872808808     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Baumeister SE, Völzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008;134:85-94.
2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
4. Wong VW, Chu WC, Wong GL, et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409-15.
5. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
6. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-31.
7. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of nonalcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012;56:234-40.
8. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using noninvasive biomarkers (FibroTest). BMC Gastroenterol 2010;10:40.
9. de Lédinghen v, Ratziu V, Causse X, et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol 2006;45:592-9.
10. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609.
11. Frith J, Day CP, Henderson E, Burt AD, Newton JL. Nonalcoholic fatty liver disease in older people. Gerontology 2009;55:607-13.
12. Sookolan S, Pirola CJ. Meta-analysis of the influence of 1148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94.
13. Liu CJ. Prevalence and Risk Factors for nonalcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27:1555-60.
14. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
15. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9.
16. Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009;51:371-9.
17. Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2011;35:23-8.
18. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011;54:463-71.
19. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
20. Ratziu V, Bonyhay L, Martino V Di, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93.
21. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests dunng a 28-year follow-up. Hepatology 2010;51:595-602.
22. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-53.
23. Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012;55:1406-15.